Literature DB >> 15180871

Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria.

Jan Simak1, Karel Holada, Antonio M Risitano, Jan H Zivny, Neal S Young, Jaroslav G Vostal.   

Abstract

We analysed endothelial cell membrane microparticles (ECMP) in the peripheral blood of patients with paroxysmal nocturnal haemoglobinuria (PNH) (n = 9), aplastic anaemia (AA) (n = 10), sickle cell disease (SCD) (n = 8), and healthy donors (HD) (n = 11). There was no clinically manifested thrombosis in the PNH or AA group, except one cured thrombophlebitis (PNH), while all SCD patients had a history of vaso-occlusive crises. We used three-colour flow cytometry with blood cell-specific antibodies and antibodies to endothelial antigens CD105 and CD144. Phosphatidylserine-positive microparticles were detected using the annexin V-binding (AVB) assay. The population of CD105+AVB+ ECMP was significantly (P < 0.05) higher in SCD (median: 0.568 x 10(9)/l; 25-75th percentile range: 0.351-0.976 x 10(9)/l) and PNH (0.401 x 10(9)/l; 0.19-0.441 x 10(9)/l) patients when compared with AA (0.122 x 10(9)/l; 0.061-0.172 x 10(9)/l) or HD (0.180 x 10(9)/l; 0.137-0.217 x 10(9)/l) group. Even more pronounced differences were observed in ECMP exhibiting a marker of inflammatory stimulation CD54 (CD105+CD54+). Similarly, ECMP that exhibited endothelial specific and proteolysis-sensitive antigen CD144 were increased in SCD and PNH, but not in AA. Elevated CD54+ ECMP may reflect the inflammatory status of endothelial cells in SCD and PNH, while CD144+ ECMP could indicate continuous endothelial stimulation and/or injury. Analysis of circulating ECMP appears promising to provide useful information on the status of the vascular endothelium in PNH and SCD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180871     DOI: 10.1111/j.1365-2141.2004.04974.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  34 in total

1.  Red blood cell microparticles: clinical relevance.

Authors:  Olivier Rubin; Giorgia Canellini; Julien Delobel; Niels Lion; Jean-Daniel Tissot
Journal:  Transfus Med Hemother       Date:  2012-08-27       Impact factor: 3.747

2.  Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience.

Authors:  Deniz Goren Sahin; Olga Meltem Akay; Muzaffer Keklik; Vahap Okan; Abdullah Karakus; Cengiz Demir; Mehmet Ali Erkurt; Kadir Ilkkilic; Rahsan Yildirim; Gulsum Akgun Cagliyan; Salih Aksu; Mehmet Hilmi Dogu; Mehmet Sinan Dal; Volkan Karakus; Ali Ihsan Gemici; Hatice Terzi; Engin Kelkitli; Serdar Sivgin; Ali Unal; Mehmet Yilmaz; Orhan Ayyildiz; Serdal Korkmaz; Bulent Eser; Fevzi Altuntas
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

Review 3.  Hypercoagulability and thrombotic complications in hemolytic anemias.

Authors:  Kenneth I Ataga
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

Review 4.  Microparticle analysis in disorders of hemostasis and thrombosis.

Authors:  Micah J Mooberry; Nigel S Key
Journal:  Cytometry A       Date:  2015-02-20       Impact factor: 4.355

Review 5.  Extracellular vesicles and blood diseases.

Authors:  Shosaku Nomura
Journal:  Int J Hematol       Date:  2017-01-27       Impact factor: 2.490

6.  Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria.

Authors:  Morag Griffin; Peter Hillmen; Talha Munir; Stephen Richards; Louise Arnold; Kathryn Riley; Anita Hill
Journal:  Haematologica       Date:  2018-10-04       Impact factor: 9.941

7.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

8.  Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Authors:  Dominique Helley; Régis Peffault de Latour; Raphaël Porcher; Celso Arrais Rodrigues; Isabelle Galy-Fauroux; Jeanne Matheron; Arnaud Duval; Jean-François Schved; Anne-Marie Fischer; Gérard Socié
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

Review 9.  Membrane microparticles: shedding new light into cancer cell communication.

Authors:  Paloma Silva de Souza; Roberta Soares Faccion; Paula Sabbo Bernardo; Raquel Ciuvalschi Maia
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-19       Impact factor: 4.553

10.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.